Tasley Pharma Leads $20M Round In Chinese Innovative Drug Developer PegBio

Pan Yue
July 17, 2017 — 13:36 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: big data China chinese diabete healthcare innovative drug investment Legend Star medicine Oriza PegBio pharmaceutical Shanghai stock exchange Suzhou Tasley Pharma United States venture capital

Related News:

China’s Alibaba, Ethiopia Sign MoU On eWTP To Boost African’s Digital Economy

November 27, 2019 — 10:23

A Joint Fund By Allianz Real Estate And Keppel Capital-Linked Fund To Buy Beijing Office

October 16, 2019 — 15:26

Chinese Smartphone Maker Vivo To Invest $559M For Second Plant In India

December 14, 2018 — 14:54

US Chipmaker Qualcomm Files To Further Ban Apple In China

December 14, 2018 — 14:16

Experts Share Insights On Managing Risks And Seizing Opportunities Through Belt And Road Initiative

September 14, 2018 — 08:50

CPPIB And Goodman Increase China Equity Commitment To $5B

August 23, 2018 — 11:57

Chinese News App Toutiao Considering Hong Kong IPO

July 10, 2018 — 23:16

Airbus To Develop Nanocomposite Materials For Aircraft Application In China

July 6, 2018 — 13:11

AIIB Approves $250M Loan To Modernize Irrigation in Indonesia

July 3, 2018 — 14:57

Franchising and Licensing Asia (FLAsia) 2024